Lewis Y Radioimmunotherapy Using 225Ac for Safer Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing anti-LeY antibody therapies face challenges with suboptimal warheads that compromise clinical safety and efficacy, leading to limited tumor targeting and toxicity issues.
Innovation Solution
Development of a novel radio-conjugate approach using LeY targeting agents, such as monoclonal antibodies, peptides, or small molecules, labeled with specific radioisotopes like 225Ac, for diagnosing and treating LeY-positive cancers, combined with therapeutic agents to enhance efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-LeY antibody therapies use conventional warheads (e.g., calicheamicin, Pseudomonas exotoxin), then the antibody can be developed as an armed therapy, but clinical safety and efficacy are compromised due to toxicity and immunogenicity issues
Solution Approach 1:
The patent changes the fundamental parameter of the warhead from conventional chemical/cytotoxic agents to radioisotopes (e.g., 177Lu, 90Y, 131I). This parameter change transforms the mechanism of action from direct cytotoxicity to radiation-mediated cell death, thereby improving clinical safety and reducing toxicity while maintaining therapeutic efficacy against LeY-expressing tumors
Solution Approach 2:
The patent replaces the conventional mechanical/chemical warhead system with a radiation-based system. The radioisotope emits radiation that destroys tumor cells through physical energy deposition, substituting the need for toxic chemical agents and reducing immunogenicity issues associated with protein-based toxins
2Reliability
If anti-LeY antibodies are used to target tumors, then tumor targeting capability is achieved, but limited uptake in normal tissues occurs due to LeY expression on normal epithelial cells
Solution Approach 1:
The patent applies local quality by selecting radioisotopes with specific radiation characteristics that deliver high linear energy transfer (LET) radiation with short range. This creates a localized radiation effect at the tumor site while minimizing damage to surrounding normal tissues, thereby improving tumor targeting specificity despite LeY expression on normal cells
Solution Approach 2:
The patent converts the harmful effect of LeY expression on normal tissues into a benefit by using internalizing antibodies that deliver radiation inside cells. The radiation effect is concentrated within the cell membrane and cytoplasm where LeY is expressed, transforming the problematic normal tissue expression into a site of controlled therapeutic action
3Power
If hu3S193 is engineered as an antibody drug-conjugate (ADC), then therapeutic activity is enhanced, but tumor-binding activity is lost and biodistribution profile changes
Solution Approach 1:
The patent extracts the warhead function from the antibody molecule by using radioisotopes that can be conjugated to the antibody. This separation allows the antibody to maintain its native tumor-binding properties while the radioisotope provides the therapeutic effect, avoiding the loss of binding activity that occurs with traditional ADC constructs
Solution Approach 2:
The patent achieves multi-functionality by combining the tumor-targeting function of the anti-LeY antibody with the therapeutic radiation function of the radioisotope in a single conjugate system. This universal approach allows the same antibody platform to maintain both binding activity and therapeutic efficacy without the compromises of traditional ADC designs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel radio-conjugate approach provides targeted cancer treatment with improved potency and safety, allowing for effective administration of radiation doses tailored to individual patients, enhancing treatment outcomes for LeY-positive cancers.
Implementation Method 1
labeled with a radioisotope... allowing for effective administration of radiation doses
Implementation Method 2
The novel radio-conjugate approach provides targeted cancer treatment with improved potency and safety, allowing for effective administration of radiation doses
Data Source
AI summary
Provided are compositions and methods for treating Lewis Y antigen positive cancers in mammalian subjects by administering an effective amount of a radionuclide-labeled Lewis Y antigen targeting agent such as an antibody labeled with an alpha particle-emitting radionuclide such as 225Ac. The methods may further include administration of additional agents, such as radiosensitizing agents, immune checkpoint therapies, CD47 blockades, and/or DNA damage response inhibitors.